We searched the databases MEDLINE, Embase, and Scopus on 1 March 2024. Comparative prehabilitation studies including patients undergoing oncological surgery were included. Prehabilitation was defined as a preoperative exercise program, alone or combined with other components, with the explicit aim of improving postoperative outcomes. Extracted outcomes included reported rationales, program content, and primary endpoints.
Preoperatively improving physical fitness is a widely used rationale for prehabilitation; however, studies are implicit in rationales for specific program components. Content and duration of prehabilitation showed considerable variation, often determined by feasibility and time to surgery. Prehabilitation studies could benefit from standardized outcomes. Adopting a more mechanistically grounded approach could improve program design and possibly effectiveness.
In total, 140 studies (N = 24,925 patients) were included. Most (N = 125, 89%) reported a rationale for improving physical fitness, particularly cardiorespiratory fitness (N = 97, 69%). Psychological (N = 46, 33%) and metabolic (N = 28, 20%) rationales were reported less frequently. Rationales for specific attributes (e.g., intensity) were rarely described. Exercise was predominantly supervised (N = 57, 41%), and of these supervised sessions, most were prescribed three times per week (N = 25, 44%). Almost all studies (N = 121, 86%) included anaerobic exercise component at moderate-intensity continuous (N = 39, 32%) or high-intensity interval (N = 34, 28%) mode. Intended duration varied from 1 to 12 weeks. Most reported primary endpoints were surgical outcomes (e.g., complications) (N = 59, 42%), although definitions varied.
Prehabilitation aims to improve patients' resilience to surgery and enhance postoperative recovery. Understanding rationales for prehabilitation content may identify opportunities for program optimization. This systematic review provides an overview of rationales, intervention, and outcomes used in prehabilitation studies in oncological populations.
The review was preregistered in International Prospective Register of Systematic Reviews (PROSPERO; CRD42024512892).
This website uses cookies to ensure you get the best experience on our website.